TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA approved bepirovirsen (Hibsago) for certain adults with chronic hepatitis B, to be used alongside existing antiviral therapy. In phase III trials, about 19% to 20% of eligible participants reached a functional cure by week 72, compared with none in the placebo group; the drug carries serious safety warnings and requires regular blood tests.
The FDA approved bepirovirsen (Hibsago) on Tuesday for some adults with chronic hepatitis B, allowing it to be used alongside existing antiviral treatment. The decision was based on two phase III trials in which about one in five eligible participants achieved a functional cure by week 72; the approval is limited to patients meeting specific treatment and disease criteria and comes with warnings for serious adverse effects.
The approval covers adults with chronic hepatitis B who have no cirrhosis, have taken nucleos(t)ide analog antiviral therapy for at least six months, have suppressed hepatitis B virus levels in their blood, and have hepatitis B surface antigen (HBsAg) levels of 3,000 IU/mL or less. Bepirovirsen is prescribed in addition to that antiviral therapy, rather than as a replacement at the outset.
In the B-Well 1 and B-Well 2 phase III trials, 19% to 20% of participants with HBsAg levels of 3,000 IU/mL or less achieved a functional cure at week 72 while receiving bepirovirsen with background antivirals. No participants in the placebo group did so, according to the report. Among trial participants with HBsAg levels of 1,000 IU/mL or less, the functional-cure rate was 26%. The report does not specify here how many people were included in each subgroup.
Bepirovirsen is given over a six-month course. The report says patients can self-administer it after the first dose. Common side effects include injection-site reactions, fatigue, fever and headache. The FDA-approved prescribing information carries a boxed warning for serious hepatic flares during treatment and low platelet counts that can lead to life-threatening thrombocytopenia. Regular blood tests are required, and the drug is not recommended for people with hepatitis D coinfection.
A New Route Toward Treatment-Free Control
For people who meet the approved criteria, the main potential benefit is the possibility of maintaining control of hepatitis B after chronic treatment ends. The FDA describes the treatment as offering some patients the possibility of continued viral control after all chronic hepatitis B treatment has stopped. That is distinct from saying every patient will clear the virus or can discontinue antivirals: the trial result was achieved by a minority of eligible participants, and the reported outcome was measured at week 72.
The development matters because chronic hepatitis B can lead to serious liver disease, including cirrhosis, and the source report says hepatitis B accounts for more than half of liver cancer cases worldwide. At the same time, the safety warnings make this a treatment requiring clinical oversight, not a simple one-time cure. Eligibility limits, monitoring and the chance that treatment will not produce a functional cure will shape its use.
As an affiliate, we earn on qualifying purchases.
Who the Approval Covers
The FDA action is based on the B-Well 1 and B-Well 2 trials, which compared bepirovirsen plus existing antiviral therapy with placebo plus background treatment. The approval applies to adults with suppressed HBV blood levels and HBsAg levels no higher than 3,000 IU/mL, who have already taken antiviral therapy for at least six months and do not have cirrhosis. It does not describe bepirovirsen as a stand-alone substitute for current antivirals when treatment begins.
The trial results also varied by HBsAg level. The reported 26% functional-cure rate was in the subgroup at or below 1,000 IU/mL; it should not be read as the rate for all people with chronic hepatitis B. The source report estimates that this lower-antigen group represents about 45% of diagnosed cases worldwide, but does not provide further detail on how that estimate was calculated.
FDA Center for Drug Evaluation and Research official Wendy Carter said the treatment offers some patients a possibility of maintaining viral control after chronic HBV treatment ends and called the approval an advance for people living with the disease. Trial investigator Norah Terrault, of the University of Southern California’s Keck School of Medicine, described the approval as the start of a new era and said the potential for functional cure after a short treatment period had long been a goal for patients and physicians. Those statements reflect the treatment’s potential; the reported trial outcomes show that most participants did not reach functional cure.
“Bepirovirsen offers patients the potential to achieve functional cure after a short period of treatment, a long-standing goal for patients and physicians alike.”
— Norah Terrault, MD, trial investigator at the University of Southern California’s Keck School of Medicine, in a statement from GSK
As an affiliate, we earn on qualifying purchases.
Limits of the Trial Results
The available report does not give the total number of trial participants, detailed subgroup sizes, or the full statistical analysis behind the reported response rates. It also does not establish from the information provided how durable functional cure will be beyond the week 72 assessment, or which individual patients are most likely to benefit. The FDA approval does not mean that all patients can stop antivirals or that the virus has been eradicated in every person who responds.
Serious safety risks remain part of the treatment decision. The prescribing information warns about hepatic flares and low platelet counts, as well as worsening kidney function, serious inflammatory reactions such as vasculitis and risks from improper injection. The source report says regular blood tests are required but does not specify their schedule. Bepirovirsen is not recommended for patients with hepatitis D coinfection.
As an affiliate, we earn on qualifying purchases.
Monitoring During the Six-Month Course
Eligible patients and their clinicians will need to review the FDA-approved prescribing information, assess whether the treatment criteria are met, and plan the required blood-test monitoring. The course lasts six months, with the first dose administered before self-administration is permitted, according to the report. Clinicians will also need to weigh the potential for treatment-free viral control against the boxed warning and other listed risks.
Further details about the trial populations, longer-term outcomes and how clinicians should determine whether a patient has achieved a durable functional cure are not included in the source report. Those questions will matter as use of the newly approved treatment begins.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who can receive FDA-approved bepirovirsen?
The approval is for adults with chronic hepatitis B who have no cirrhosis, have taken antiviral therapy for at least six months, have suppressed HBV blood levels and have HBsAg levels of 3,000 IU/mL or less. It is used alongside nucleos(t)ide analog antiviral therapy.
Does the approval mean bepirovirsen cures everyone with hepatitis B?
No. In the reported phase III trials, 19% to 20% of eligible participants reached functional cure by week 72, compared with none in the placebo group. The result was not achieved by most participants, and the report does not establish that every response will be permanent.
How is bepirovirsen given?
The approved treatment is a six-month course. The report says patients can self-administer it after the first dose. The source does not provide further dosing instructions.
What safety warnings come with the drug?
The FDA-approved information includes a boxed warning for serious hepatic flares and low platelet counts that can cause life-threatening thrombocytopenia. Other listed risks include worsening kidney function, inflammatory reactions such as vasculitis and problems from improper injection. Regular blood tests are required.
Can people with hepatitis D coinfection use bepirovirsen?
The report says bepirovirsen is not recommended for patients with hepatitis D virus coinfection.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
